Grade II gliomas taking temozolomide for a year and then stopping may have problems with recurrence.
Grade II gliomas need to be determined by the extent of surgical resection and the patient’s age to determine the duration of chemotherapy. If the patient is young and the tumor is located in the frontal lobe expanding completely resected, regular review can be considered after the end of chemotherapy.
If not, there is a higher possibility of recurrence and malignancy of grade II glioma. After one year of oral temozolomide discontinuation may recur, and regular imaging is needed to determine whether there is a problem of recurrence.
Temozolomide is an antitumor active drug that can be used in the treatment of gliomas, usually in combination with radiotherapy, and subsequently this drug can be used as a maintenance therapy. When this drug is applied, it is important to note that it should not be used in patients who are allergic to this product, women during pregnancy, and patients with the presence of bone marrow suppression.
The most common adverse reactions of temozolomide are nausea and vomiting, and some patients may experience bone marrow suppression, but it may disappear on its own after stopping the drug, so patients are advised to take regular blood tests during the use of the drug to determine the number of white blood cells and platelets.
It is recommended that patients should consult the neurosurgery department of regular hospitals in a timely manner after the discovery of glioma, and the medication should follow the doctor’s prescription, and should not be used or stopped without authorization.